An interventional study of Influenza vaccine and Placebo in Acute Coronary Syndromes (ACS), sponsored by Tongji Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by Tongji Hospital · Not applicable, Interventional, and Prevention
The goal of this clinical trial is to learn if influenza vaccination can prevent adverse cardiac events in Chinese acute coronary syndrome patients. The main questions it aims to answer are:
If there is a comparison group: Researchers will compare influenza vaccination and placebo to see if adverse cardiac events decrease.
Participants will receive an influenza vaccination or placebo after enrollment and phone calls for follow-up at 1 month, 3 months, 6 months and 1 year after discharge.
1,461 studies on the registry are indexed under Acute Coronary Syndrome; 267 are open to participants now.
This study's planned enrollment of 6,620 is above the median of 200 across 869 interventional studies indexed under Acute Coronary Syndrome.
Browse Acute Coronary Syndrome studies →Tongji Hospital is the lead sponsor of 373 studies on the registry; 204 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
patients will receive influenza vaccination
Drug: Influenza vaccine
patients will receive placebo (PBS)
Drug: Placebo
Patients receive injection of 0.5ml influenza vaccine
Patients will receive injection of 0.5ml PBS
Composite endpoint of cardiovascular death, myocardial infarction or stroke
The number of participants with cardiovascular death, myocardial infarction or stroke (first occurring) till 12 months.
Time frame: 12 months
all cause death
The number of participants with all cause death till 12 months
Time frame: 12 months
cardiovascular death
The number of participants with cardiovascular death till 12 months
Time frame: 12 months
stroke
The number of participants with stroke till 12 months
Time frame: 12 months
myocardial infarction
The number of participants with myocardial infarction till 12 months
Time frame: 12 months
unplanned hospitalization for heart failure or for arrhythmia
The number of participants with unplanned hospitalization for heart failure or for arrhythmia till 12 months
Time frame: 12 months
unplanned revascularization
The number of participants with unplanned revascularization till 12 months
Time frame: 12 months
stent thrombosis
The number of participants with stent thrombosis till 12 months
Time frame: 12 months
influenza like illness
The number of participants with fever (body temperature ≥38℃) accompanied by cough or sore throat till 12 months
Time frame: 12 months
hospitalization for influenza
The number of participants with hospitalization for influenza till 12 months
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tongji Hospital